← IndicationsOpen filtered programs
Landscape
Genetic Hearing Loss
Genetic Hearing Loss has 27 tracked records across 9 named organizations, including 4 strong-evidence records and 7 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
27
Pipeline Records
strong evidence + caveats + candidates
4
Strong Evidence
23 checked records with caveats
7
Active Programs
currently active
1
Marketed / Approved
commercial or approved
9
Organizations
companies, sponsors, and institutions
Competitive Density
35/100
organization breadth + program volume
Pipeline Velocity
19/100
active and late-stage share
Evidence Coverage
15/100
share strong evidence
Completion Signal
7/100
late-stage, approved, or marketed
Attrition Rate
15/100
share discontinued
Concentration
52/100
top-organization share
Programs by Stage
Preclinical6 · 22%
Early Phase 11 · 4%
Phase 1/22 · 7%
Phase 24 · 15%
Phase 2/31 · 4%
Interventional/NA3 · 11%
Approved1 · 4%
Observational/NA2 · 7%
Not applicable7 · 26%
Trial / Program Status
Active7 · 26%
Approved1 · 4%
Completed5 · 19%
Discontinued4 · 15%
Unknown10 · 37%
Modality Breakdown
Gene Therapy12 · 44%
Small Molecule5 · 19%
Diagnostic2 · 7%
Genetic/Biomarker Study2 · 7%
Genetic/Diagnostic Sequencing2 · 7%
Biomarker/Specimen Collection1 · 4%
Cochlear/Auditory Implant1 · 4%
Genetic Screening Test1 · 4%
RNA Therapy1 · 4%
Program Types
Therapeutic18 · 67%
Diagnostic8 · 30%
Device1 · 4%
Top Organizations
Institution-led study14 · 52%
Eli Lilly and Company3 · 11%
Regeneron Pharmaceuticals3 · 11%
Sensorion2 · 7%
HuidaGene Therapeutics Co., Ltd.1 · 4%
Khondrion BV1 · 4%
Otonomy1 · 4%
OtoVia Therapeutics1 · 4%
Population Tags
genetic26 · 96%
pediatric20 · 74%
congenital11 · 41%
adult9 · 33%
pre-lingual8 · 30%
bilateral4 · 15%
otof-dfnb94 · 15%
profound4 · 15%
syndromic3 · 11%
cochlear-implant2 · 7%
Strong-Evidence Programs
4 recordsOtarmeni by RegeneronStrong evidence
Company: Regeneron Pharmaceuticals · Approved · Approved
Gene TherapyApprovedApproved99% confidence
AK-OTOF by Eli Lilly and AkouosStrong evidence
Company: Eli Lilly and Company · Phase 2 · Active
Gene TherapyPhase 2Active95% confidence
SENS-501 by SensorionStrong evidence
Company: Sensorion · Phase 1/2 · Active
Gene TherapyPhase 1/2Active94% confidence
GJB2-GT by SensorionStrong evidence
Company: Sensorion · Preclinical · Active
Gene TherapyPreclinicalActive88% confidence
Checked Records With Caveats
23 recordsOTO-825 by Otonomy
Company: Otonomy · Preclinical · Discontinued
Gene TherapyPreclinicalDiscontinued87% confidence
EHT102 by EuHearingStatus caveat
Company: Shanghai EuHearing Therapeutics Co., Ltd · Phase 1/2 · Active
Gene TherapyPhase 1/2Active90% confidence
OTOV101N + OTOV101C by OtoVia TherapeuticsStatus caveat
Company: OtoVia Therapeutics · Interventional/NA · Unknown
Gene TherapyInterventional/NAUnknown86% confidence
AP-HP OTOPLAT platinum ototoxicity pharmacogenetics studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Genetic/Biomarker StudyNot applicableCompleted88% confidence
Nantong newborn deafness-gene screening cohortStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Active
Genetic Screening TestNot applicableActive88% confidence
HG205 RNA base-editing therapy by HuidaGeneStatus caveat
Company: HuidaGene Therapeutics Co., Ltd. · Early Phase 1 · Discontinued
RNA TherapyEarly Phase 1Discontinued88% confidence
UNC NC NEXUS newborn exome sequencing studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Genetic/Diagnostic SequencingNot applicableCompleted88% confidence
Dominant deafness genetic epidemiology blood-sample studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Genetic/Biomarker StudyNot applicableCompleted87% confidence
Cochlear implant stimulation-parameter physiology studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Cochlear/Auditory ImplantNot applicableCompleted87% confidence
KH176 by Khondrion for m.3243A>G mitochondrial diseaseStatus caveat
Company: Khondrion BV · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
CMV perilymphatic-fluid diagnostic study during cochlear implantationStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Unknown
Biomarker/Specimen CollectionNot applicableUnknown84% confidence
Colorado SLOS Cholesterol and Antioxidant StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Unknown
Small MoleculePhase 2Unknown84% confidence
Fudan EH002 OTOF gene therapy studyStatus caveat
Sponsor / Institution: Institution-led study · Interventional/NA · Active
Gene TherapyInterventional/NAActive84% confidence
Hearing-impairment exome sequencing studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Unknown
Genetic/Diagnostic SequencingNot applicableUnknown84% confidence
Hadassah Wolfram Syndrome Type 2 Combination Therapy StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Unknown
Small MoleculePhase 2Unknown84% confidence
Jessa DFNA9 Vestibulopathy Imaging and Genetics StudyStatus caveat
Sponsor / Institution: Institution-led study · Observational/NA · Active
DiagnosticObservational/NAActive84% confidence
GJB2 hearing loss gene therapy by Eli LillyStatus caveat
Company: Eli Lilly and Company · Preclinical · Unknown
Gene TherapyPreclinicalUnknown82% confidence
National Taiwan University Proton Pump Inhibitor SLC26A4 Hearing-Loss StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2/3 · Unknown
Small MoleculePhase 2/3Unknown82% confidence
AK-CLRN1 by Eli LillyStatus caveat
Company: Eli Lilly and Company · Preclinical · Unknown
Gene TherapyPreclinicalUnknown80% confidence
AAV.103 by RegeneronStatus caveat
Company: Regeneron Pharmaceuticals · Preclinical · Unknown
Gene TherapyPreclinicalUnknown78% confidence